EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Exelixis (EXEL) shares rose 7.4% after the company reported positive top-line results from its phase III STELLAR-303 study for zanzalintinib in combination with Tecentriq for previously non-microsatellite instability-high metastatic colorectal cancer. The trial demonstrated a statistically significant overall survival benefit for the combination compared to regorafenib, a current standard of care. This outcome represents a pivotal milestone for Exelixis, enhancing the likelihood of regulatory success for zanzalintinib and supporting the company's strategic efforts to diversify its oncology pipeline beyond its lead drug, Cabometyx.

Analysis

Exelixis (EXEL) experienced a significant 7.4% share price increase following the release of positive top-line results from its phase III STELLAR-303 study. The trial demonstrated that the combination of its investigational drug, zanzalintinib, with Tecentriq achieved a statistically significant improvement in overall survival (OS) for the intent-to-treat population with metastatic colorectal cancer when compared against the standard-of-care, regorafenib. This result marks a pivotal milestone in the zanzalintinib development program, substantially increasing the probability of regulatory approval and validating the company's strategic effort to diversify beyond its lead drug, Cabometyx. While one of the two dual primary endpoints was met, the trial will continue to a final analysis for the second primary endpoint—OS in the subgroup of patients without liver metastases—which remains a key future catalyst. The company's stock has already shown considerable strength, gaining 30.2% year-to-date in stark contrast to the industry's 3.4% decline, indicating strong investor confidence in its pipeline progress.

Key Decisions for Investors

• The positive Phase III data materially de-risks the zanzalintinib asset and strengthens the long-term growth narrative for Exelixis, supporting a continued bullish stance on the company's diversification strategy.
• Investors should closely monitor the upcoming final analysis of the second primary endpoint, as a positive result in the non-liver metastases subgroup could unlock further upside, while a failure could introduce downside risk.
• Given the stock's significant outperformance year-to-date, consider that near-term catalysts may be partially priced in, but the successful trial significantly reduces the company's long-term reliance on Cabometyx, improving its fundamental risk profile.